case_images: PMC6458881_01
case_images: Recurrent lesion before ECT treatment.
case_images: CRIONM2019-2507642.001.jpg
case_images: PMC6458881_01_CRIONM2019-2507642.001.jpg
case_images: fig1
case_images: After a month from the surgery, in May 2015, a new nodule appeared in correspondence of the graft, suggesting a recurrence (Figure 1).
case_images: Eschar after ECT treatment.
case_images: CRIONM2019-2507642.002.jpg
case_images: PMC6458881_01_CRIONM2019-2507642.002.jpg
case_images: fig2
case_images: ECT treatment, the mass diminished in diameter and appeared completely necrotized (Figure 2). Eight weeks after treatment, all that remained was an eschar that detached, leaving an erythematous zone of reepithelialization (Figure 3).
case_images: Eschar detached.
case_images: CRIONM2019-2507642.003.jpg
case_images: PMC6458881_01_CRIONM2019-2507642.003.jpg
case_images: fig3
case_images: ECT treatment, the mass diminished in diameter and appeared completely necrotized (Figure 2). Eight weeks after treatment, all that remained was an eschar that detached, leaving an erythematous zone of reepithelialization (Figure 3).
case_images: Restitutio ad integrum.
case_images: CRIONM2019-2507642.004.jpg
case_images: PMC6458881_01_CRIONM2019-2507642.004.jpg
case_images: fig4
case_images: This area disappeared within three months, with a complete restitutio ad integrum (Figure 4).